---
title: "biote Corp. | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 47.96 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264497956.md"
datetime: "2025-11-05T21:14:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264497956.md)
  - [en](https://longbridge.com/en/news/264497956.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264497956.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264497956.md) | [繁體中文](https://longbridge.com/zh-HK/news/264497956.md)


# biote Corp. | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 47.96 M

Revenue: As of FY2025 Q3, the actual value is USD 47.96 M, beating the estimate of USD 47.76 M.

EPS: As of FY2025 Q3, the actual value is USD 0.22, beating the estimate of USD 0.0467.

EBIT: As of FY2025 Q3, the actual value is USD 11 M.

### Revenue

-   Total revenue for Q3 2025 was $48.0 million, a decrease of 6.7% from $51.4 million in Q3 2024.
-   Procedure revenue declined by 10.4%, partially offset by an 8.4% growth in dietary supplements revenue.

### Gross Profit Margin

-   Gross profit margin improved to 71.8% from 70.3% in the prior year period.

### Operating Income

-   Operating income decreased by 32.1% to $8.3 million due to reduced gross profit and higher operating expenses.

### Net Income

-   Net income for Q3 2025 was $9.2 million, compared to $12.7 million in Q3 2024.
-   Diluted earnings per share attributable to biote Corp. stockholders was $0.22, compared to $0.33 in the prior year period.

### Adjusted EBITDA

-   Adjusted EBITDA was $12.9 million, a decrease of 20.5% from $16.2 million in Q3 2024.
-   Adjusted EBITDA margin was 26.9%, down from 31.5% in the prior year period.

### Cash Flow

-   Net cash provided by operating activities for the nine months ended September 30, 2025, was $27.6 million, compared to $32.9 million in the prior year period.
-   Net cash used in investing activities for the nine months ended September 30, 2025, was - $4.5 million, compared to - $17.5 million in the prior year period.
-   Net cash used in financing activities for the nine months ended September 30, 2025, was - $34.4 million, compared to - $66.1 million in the prior year period.

### Unique Metrics

-   Repurchased approximately one million shares of Class A common stock in Q3 2025.
-   Amended settlement agreements with Marci Donovitz and Dr. Gary Donovitz to repurchase their remaining shares at a savings compared to the original agreements.

### Outlook / Guidance

-   Biote reiterates its 2025 financial outlook, forecasting revenue above $190 million and Adjusted EBITDA above $50 million.
-   2025 procedure revenue is expected to decrease at a high single-digit percentage rate from 2024, while dietary supplements revenue is expected to grow at a mid-teens percentage rate from 2024.

### Related Stocks

- [biote Corp. (BTMD.US)](https://longbridge.com/en/quote/BTMD.US.md)

## Related News & Research

- [Biote Q4 revenue slightly beats estimates](https://longbridge.com/en/news/278773697.md)
- [Dietary Supplements Market to Reach USD 478.7 Billion by 2036 as Personalized Nutraceuticals and Digital Health Diagnostics Surge | FMI](https://longbridge.com/en/news/280788367.md)
- [Australia to consider using a mechanism if there is a gas shortfall in Q3](https://longbridge.com/en/news/281420207.md)
- [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/en/news/281225115.md)
- [Nike Takes 'Intentional' Hit To Clear 'Unhealthy Inventory' In Q3 As CEO Eyes Turnaround By Year-End](https://longbridge.com/en/news/281362844.md)